JCO Global Oncology最新文献

{"title":"Characteristics and Impact of p16 Expression in Patients With Oropharyngeal Squamous Cell Carcinoma in Tanzania.","authors":"Godwin Nnko, Saloni Patel, Eulade Rugengamanzi, Shafii S Ramadhani, Dammy A Shimbo, Mathias Banzi, Godfrey Malangwa, Getruda Mashashi, Glory Makupa, Milpah Moturi, Leila Mwakipunda, Jesse Jonathan, Aisha Ramadhani, Mwitasrobert Gisiri, Cepheline Idrissa, Nur Antar Mabruk, Angela Karia, Innocent Sifueli, Harrison Chuwa, Alexis A Miller, Jerry Ndumbalo","doi":"10.1200/GO-24-00652","DOIUrl":"https://doi.org/10.1200/GO-24-00652","url":null,"abstract":"<p><strong>Purpose: </strong>Oropharyngeal cancer is on the rise, despite declines in other head and neck cancers. The primary cause of this increase is human papillomavirus (HPV) infection, which accounts for over a quarter of new cancer patients in Tanzania. These cancers are largely preventable through HPV vaccination. HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is recognized as a distinct molecular and clinical entity, with unique demographics, staging, survival, and prognosis. International guidelines recommend that all staging, prognosis, and treatment decisions for OPSCC occur after determining the p16 expression, a surrogate immunohistochemical marker for HPV infection. However, current Tanzanian guidelines and clinical practice do not incorporate p16 immunohistochemistry (IHC) testing, despite the availability of qualified pathologists and laboratories.</p><p><strong>Patients and methods: </strong>This retrospective hospital-based cohort study was conducted at the Ocean Road Cancer Institute (ORCI) and Muhimbili National Hospital in Dar es Salaam, Tanzania. A total of 83 patients with OPSCC were included. We assessed the sociodemographic and clinicopathologic profiles and the impact of p16 expression on overall survival (OS) in patients with OPSCC treated at the ORCI.</p><p><strong>Results: </strong>The prevalence of p16-positive OPSCC was found to be 43.4%. Patients with p16-positive tumors were younger and predominantly male and had a 3-year OS of 36% compared with 16.6% in those with p16-negative tumors.</p><p><strong>Conclusion: </strong>Our findings support the use of p16 IHC as a prognostic biomarker for OPSCC. In addition, the high prevalence of p16-positive OPSCC in our cohort suggests the broader implementation of gender-neutral HPV vaccination across Tanzania.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400652"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adoption and Implementation of Affordable Cancer Technologies in El Salvador: Identifying Implementation Strategies for Successful Cervical Cancer Prevention in Resource-Limited Settings.","authors":"Montserrat Soler, Karla Alfaro, Juan Carlos Rauda, Elizabeth Torres, José Roberto Pérez, Freddy Méndez, Gabriel Conzuelo Rodriguez, Marina A Chacon, Mayra Patricia Erazo, Rachel Masch, Eveline Mumenthaler, Miriam Cremer","doi":"10.1200/GO-25-00065","DOIUrl":"10.1200/GO-25-00065","url":null,"abstract":"<p><p>As part of the affordable cancer technology program, our team developed and tested a portable thermal ablation (TA) cervical precancer treatment. This research helped support subsequent implementation of the technology in El Salvador. Here, we review successful implementation strategies deployed during the process and point to challenges and implications for other low- and middle-income countries (LMICs). We use the exploration, preparation, implementation, and sustainment framework to guide the discussion and identify associated implementation strategies used during each phase. Significant strategies were the development and maintenance of multi-actor partnerships and accessing new funding to introduce innovations to the country. In this case, planning for implementation began before the decision to adopt TA. The case of El Salvador highlights the need for such pragmatic approaches to shorten the time between scientific research and clinical practice in LMICs. The impact of these efforts has been significant: El Salvador has gone from one of the countries with the lowest cervical cancer screening rates in the region to one that can potentially meet elimination targets in the coming decades. This experience can serve as a blueprint for cervical cancer control efforts in other LMICs.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500065"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cascade Testing Among Patients With Breast Cancer: Current Situation and Challenges in Latin America.","authors":"Rosa María Alvarez-Gómez, Alexandra Garcilazo-Reyes, Federico Avila-Moreno, Oscar Gerardo Arrieta-Rodriguez, Paula Anel Cabrera Galeana, Claudia Haydeé Arce-Salinas","doi":"10.1200/GO-24-00387","DOIUrl":"https://doi.org/10.1200/GO-24-00387","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is a significant public health issue worldwide, with a particularly high impact in Latin America (LATAM). Genetic risk assessment and germline molecular testing for pathogenic variants in actionable genes are established practices for managing breast cancer risk. Cascade testing, genetic testing of at-risk relatives of individuals carrying these variants, provides a pivotal strategy for cancer prevention and early detection.</p><p><strong>Design: </strong>This review examines the status of cascade testing among patients with breast cancer in LATAM, highlighting the barriers to its implementation and identifying opportunities to expand its application in the region.</p><p><strong>Results: </strong>Despite growing awareness of the importance of genetic risk assessment, the adoption of cascade testing remains limited in LATAM. Key barriers include restricted access to genetic services, financial and infrastructural limitations within public health systems, and sociocultural factors. However, locally driven initiatives that integrate genetic counseling into national health systems and emphasize education for health care providers have demonstrated the potential to foster long-term sustainability. The role of artificial intelligence and machine learning in genetic counseling is emerging, offering possible solutions to optimize cascade testing, but further evidence is required to assess their impact across diverse populations.</p><p><strong>Conclusion: </strong>The successful integration of cascade testing into Latin American health care systems requires strategies rooted in local initiatives, supported by public policies, and driven by health care professionals committed to changing paradigms in cancer prevention. Sustainable approaches should prioritize capacity-building, equitable access to genetic services, and the empowerment of health care providers to recognize the transformative impact of genetic counseling on patient outcomes. By fostering regionally adapted models, LATAM can enhance hereditary cancer prevention and ultimately reduce breast cancer incidence and mortality.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400387"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Global Trends in Prostate Cancer: Disparities Across Income Levels and Geographic Regions (1990-2019).","authors":"Harshitha Dudipala, Chinmay T Jani, Sarika D Gurnani, Dan Morgenstern-Kaplan, Elizabeth Tran, Kyle Edwards, Joseph Shalhoub, Rana R McKay","doi":"10.1200/GO-25-00249","DOIUrl":"https://doi.org/10.1200/GO-25-00249","url":null,"abstract":"<p><strong>Purpose: </strong>Variability in prostate cancer (PC) incidence and mortality reflects the substantial burden of the disease, shaped by factors such as socioeconomic variables, health care access, screening practices, and therapeutic treatments. This study assesses the trends in incidence, mortality, and disability-adjusted life years (DALYs) in PC among varying country income levels and WHO regions.</p><p><strong>Methods: </strong>Global Burden of Disease Study database was used to extract age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and DALYs for PC among six WHO regions and four World Bank regions based on income levels from 1990 to 2019. Mortality-to-incidence ratios (MIRs) were computed. Joinpoint regression analysis was conducted to calculate the estimated annual percentage change.</p><p><strong>Results: </strong>Between 1990 and 2019, ASIRs increased across all income level countries, with the greatest increase in the upper-middle-income countries (+64.7%). In the past 30 years, high-income countries have consistently observed the highest ASIR (2019: 77.5 per 100,000). High mortality rates were observed in low-income countries despite low ASIR overall. ASMRs increased in low-income countries (+14.3%), compared with a decrease in high- and upper-middle-income countries. DALYs also increased in low-income countries (+13.8%) compared with a decrease in high-income countries (-25.7%). MIRs decreased in all countries, with the largest decrease in high-income countries (-50%). In 2019, the highest MIR (1 per 100,000) was observed in low-income countries.</p><p><strong>Conclusion: </strong>The divergent trends in PC outcomes across income levels, such as a rise in mortality and DALYs in low-income countries, reflect global health care inequities that highlight the urgent unmet need for improving cancer screening, diagnosis, and treatment access in resource-limited settings.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500249"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, Attitudes, and Health-Seeking Behavior for Cervical, Breast, and Oral Cancers Among Women in Jashore, Bangladesh: A Cross-Sectional Study.","authors":"Md Ragaul Azim, Evelyn Yi Ting Wong, Md Mahfujur Rahman, Md Sirajul Islam, Md Habibullah Talukder, Brian Shao Tian Woon, Taufique Joarder, Ravindran Kanesvaran, Syed Abdul Hamid","doi":"10.1200/GO-25-00304","DOIUrl":"https://doi.org/10.1200/GO-25-00304","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess cancer-related knowledge, attitudes, screening behaviors, and willingness to engage in community-based screening for cervical, breast, and oral cancers among women in rural Bangladesh, with the goal of informing the design of a scalable, national cancer screening strategy.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among 1,046 eligible women (age ≥ 30 years or married ≥ 10 years) in Nawly village, Jashore, Bangladesh. Trained interviewers administered a structured questionnaire assessing sociodemographics, cancer knowledge, attitudes, screening behaviors, and willingness to participate in organized screening. Descriptive statistics and multivariate logistic regression models identified predictors of knowledge, participation, and willingness.</p><p><strong>Results: </strong>Although 75.4% of women were aware of cervical cancer, only 28.3% correctly identified screening intervals. Awareness of breast and oral cancer screening was lower (11.5% and 6.2%, respectively). Participation in cervical cancer screening was 18.2%, and <1% for breast or oral cancer. However, willingness to participate in future community-based screening was high (>89% across all cancer types). Higher education and income were significantly associated with better knowledge and increased screening participation. Fear and misconceptions were the most common barriers among those unwilling to participate.</p><p><strong>Conclusion: </strong>Despite limited screening uptake, there is strong community readiness for organized cancer screening. These findings underscore the need for tailored education campaigns and scalable, community-based programs to enhance early cancer detection in low-resource settings such as Bangladesh.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500304"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Characteristics and Survival Outcome of Patients With Mantle Cell Lymphoma: A North Indian Tertiary Care Center Experience.","authors":"Soumyadeep Datta, Ajay Gogia, Atul Sharma, Naveet Wig, Ritu Gupta, Hari Krishna Raju Sagiraju, Saumyaranjan Mallick","doi":"10.1200/GO-24-00654","DOIUrl":"https://doi.org/10.1200/GO-24-00654","url":null,"abstract":"<p><strong>Purpose: </strong>Mantle cell lymphoma (MCL) is a rare aggressive variant of non-Hodgkin lymphoma. Clinical and survival data from India are scarce.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed clinicopathologic data of 98 patients with MCL treated at our center in the past 10 years. STATA 13.0 was used for overall survival (OS) and event-free survival (EFS) assessment by Kaplan-Meier analysis. Univariate and multivariate analyses (Cox proportional hazards) were used to identify predictors of survival. <i>P</i> value < .05 defined statistical significance.</p><p><strong>Results: </strong>Median age was 60.0 years. There was extranodal involvement in 77/98 (79.0%) patients. Ninety-one of 98 (93.0%) and 54/97 (56.0%) patients, respectively, were in advanced stage (III/IV) and high-risk MCL International Prognostic Index score at presentation. There was bulky disease in 19/98 (19.0%) patients. Classical histology and interstitial/paratrabecular bone marrow (BM) infiltration was most frequent. Sixteen percent had BM without peripheral blood involvement. Most patients, 83/96 (86.0%), received rituximab-based induction chemotherapy. Fifty-one of 96 (53.0%) patients were alive with a median follow-up of 63.0 months. Median OS was 43.0 months. Estimated 3.0-year OS and EFS were 60.0% and 35.0%, respectively. Rituximab maintenance (RM) improved both OS (<i>P</i> < .01) and EFS (<i>P</i> < .01). Median OS was lower in the non-RM group (37.0 months <i>v</i> not reached; adjusted hazard ratio, 0.31 [95% CI, 0.13 to 0.72], <i>P</i> < .01). Age >60 years, Eastern Cooperative Oncology Group performance status ≥2, advanced stage, and leukocytosis at presentation were associated with poor OS.</p><p><strong>Conclusion: </strong>Our study was a comprehensive analysis of patients with MCL from India. To our knowledge, this was the first study of its kind demonstrating OS and EFS benefit of RM in MCL from this part of the world.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400654"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy Resources in Central Asia: An International Atomic Energy Agency Update.","authors":"Sondos AlKhatib, Kamal Akbarov, Varsha Hande, Olivera Ciraj-Bjelac, May Abdel-Wahab","doi":"10.1200/GO-25-00271","DOIUrl":"https://doi.org/10.1200/GO-25-00271","url":null,"abstract":"<p><strong>Purpose: </strong>Radiation therapy is crucial in cancer treatment. However, low- and middle-income countries (LMICs), including Central Asia (Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan), face increasing challenges because of limited radiation oncology resources, compounded by diverse health care systems and vast geography.</p><p><strong>Methods: </strong>A longitudinal, registry-based review analyzed the state of radiation oncology resources in Central Asia to assess current conditions and future needs, considering projected regional growth. Data were sourced from the Directory of Radiotherapy Centres (DIRAC) and GLOBOCAN 2020. A simple linear regression evaluated the relationship between machine capacity rate and Gross National Income (GNI) per capita.</p><p><strong>Results: </strong>As of 2022, the region has 75 megavoltage machines and 35 brachytherapy (BT) units, with all but two being high-dose rate BT. The number of megavoltage units per million population varies, ranging from 0.1 to 0.2 in Tajikistan, Kyrgyzstan, and Uzbekistan, and it is 2.3 in Kazakhstan. A significant correlation between GNI per capita and machine capacity was found (R² = 0.89, <i>P</i> = .014), indicating that higher GNI correlates with increased machine capacity. By 2030, a minimum of 115 megavoltage machines will be needed to meet demand, but only 75 are available as of 2022.</p><p><strong>Conclusion: </strong>While progress has been made, there remain significant challenges to ensuring equitable access to radiation therapy across Central Asia, underscoring the need for additional resources to meet growing demands.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500271"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Comes First: A Qualitative Study of Empowerment in Women Facing Breast Cancer in Ghana and Ethiopia.","authors":"Brigit D Baglien, Natalie Guzman, Eden S Kassa, Ishmael Kyei, Paa Ekow Hoyte-Williams, Mahteme Bekele, Sarah T Hawley, Mary E Byrnes, Adeyiza O Momoh","doi":"10.1200/GO-24-00624","DOIUrl":"https://doi.org/10.1200/GO-24-00624","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer is the second leading cause of cancer-related mortality among women in sub-Saharan Africa (SSA) and an accelerating global health priority. Little is known of the empowerment process as it relates to cancer outcomes in Africa. Our study sought to explore how women in Ghana and Ethiopia experience power throughout their fight against breast cancer.</p><p><strong>Methods: </strong>Women with breast cancer (stage 0 to III) were recruited from breast cancer clinics at St Paul's Hospital Millennium Medical College in Addis Ababa, Ethiopia, and Komfo Anokye Teaching Hospital in Kumasi, Ghana. We conducted semistructured interviews in English, Amharic, and Twi using the assistance of native interpreters. Narratives were inductively analyzed in a team-based approach.</p><p><strong>Results: </strong>Forty-six total women (21 from Ethiopia and 25 from Ghana) participated in our study. Our findings highlighted empowerment was central to women's overall goal of survival and to resume their family and societal roles. Women encountered factors that decreased empowerment, such as spousal influence on choice, social isolation, and physical weakness; and women identified empowering factors, such as selecting who to divulge their cancer diagnosis to, adopting a mindset of self-reliance, and drawing on hope for the future.</p><p><strong>Conclusion: </strong>We identified several factors that facilitate or obstruct the empowerment of women facing breast cancer in Ghana and Ethiopia. It is critical we recognize this unique aspect of the patient experience to frame how we think about designing potential solutions, such as the introduction of breast reconstruction, to improve care and quality of life among survivors.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2400624"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment of Reviewers 2025.","authors":"","doi":"10.1200/GO-25-00452","DOIUrl":"https://doi.org/10.1200/GO-25-00452","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500452"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145053314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public Awareness, Knowledge, and Acceptability of Oral Cancer Screening Program in Malaysia.","authors":"Nur Diana Ab Latif, Maznah Dahlui, Jennifer Geraldine Doss","doi":"10.1200/GO-25-00259","DOIUrl":"https://doi.org/10.1200/GO-25-00259","url":null,"abstract":"<p><strong>Purpose: </strong>Oral cancer (OC) remains a significant public health concern in Malaysia, with high mortality largely because of late-stage diagnosis. Despite the introduction of a national oral cancer screening (OCS) program over 20 years ago, early detection rates remain low. This study aims to evaluate the public awareness, knowledge, and acceptability of the OCS program in Malaysia.</p><p><strong>Methods: </strong>A quantitative field study using a validated questionnaire was performed to assess awareness, knowledge, and acceptability of the OCS program among general public attending selected health clinics. Data collection took place in Samarahan and Kapit Divisions, in the state of Sarawak, Malaysia.</p><p><strong>Results: </strong>A total of 651 of 655 respondents from the general public attending five selected health clinics in Samarahan and Kapit Divisions during a 1-month period completed the questionnaires, yielding an overall response rate of 99.4%. The mean age of participants was 38 years. More than half (56.8%) were female, and 32.0% worked in the government sector. Equal proportions were of Iban (31.8%) and Malay (31.5%) ethnicity. Three quarters had heard of OC (75.0%); however, less than half had heard of OCS (45.0%). Hence, although 62.4% knew what OC is, a similar proportion (63.4%) did not know of OCS. Age group, location, employment status, and risk habits were among the sociodemographic factors significantly associated with public awareness on OC and OCS; public knowledge on risk habits and prevention of OC; and acceptability of the OCS.</p><p><strong>Conclusion: </strong>Enhancing public knowledge on OC and improving accessibility to screening especially for high-risk groups are crucial for improving early detection rates and reducing the disease burden in Malaysia.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500259"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}